Docoh
Loading...
Sign up Log in

CLDX Celldex Therapeutics

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Company profile

Ticker
CLDX
Exchange
NASDAQ
Website
www.celldex.com/
CEO
Anthony Marucci
Employees
Incorporated
Delaware
Location
New Jersey
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories • Myriad Genetics • Lantheus • Quidel • Neogen • Meridian Bioscience • Oxford Immunotec Global • Achieve Life Sciences • Intellia Therapeutics • Heska Corp. ...
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
0000744218
Corporate docs
IRS number
133191702

CLDX stock data

(
)

News

Pro users get this 30m faster
Celldex Presents Data From ILT4/PD-(L)1 Bispecific Antibody Program At AACR 2021
12 Apr 21
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021 HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the presentation of
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
30 Mar 21
50 Biggest Movers From Yesterday
30 Mar 21
Gainers
12 Health Care Stocks Moving In Monday's After-Market Session
29 Mar 21
Celldex Therapeutics Q4 EPS $(0.55) Up From $(0.64) YoY, Sales $3.80M Up From $887.00K YoY
29 Mar 21

Press releases

Pro users get this 30m faster
Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
12 Apr 21
HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the presentation of promising data from the Company's growing bispecific platform at the American Association
Biotechs Working on Potential Preventive Measures and Cancer Treatments
30 Mar 21
NEW YORK, March 30, 2021 /PRNewswire/ -- Cancer research and development are a major part of the biotechnology industry, and there is always room for improvement and growth. Recently, biotech company Perimeter Medical
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
29 Mar 21
HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020. "Celldex made
Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria
29 Mar 21
Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference
5 Mar 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Mar 21
18 Apr 21
31 Dec 21

Financial summary

Financial statements Chart CLDX financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 43.84M 43.84M 43.84M 43.84M 43.84M 43.84M
Cash burn (monthly) (positive/no burn) (positive/no burn) 8.26M 5.28M 1.74M 3.37M
Cash used (since last report) n/a n/a 29.79M 19.04M 6.26M 12.14M
Cash remaining n/a n/a 14.05M 24.8M 37.57M 31.69M
Runway (months of cash) n/a n/a 1.7 4.7 21.6 9.4

Beta Read what these cash burn values mean

Recent insider trades

CLDX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
14 Dec 20 Wright Richard M. Common Stock Sell Dispose S No No 18.6065 9,375 174.44K 208
14 Dec 20 Wright Richard M. Common Stock Option exercise Aquire M No No 2.78 9,375 26.06K 9,583
14 Dec 20 Wright Richard M. Common Stock Sell Dispose S No No 18.6065 11,457 213.17K 208
14 Dec 20 Wright Richard M. Common Stock Option exercise Aquire M No No 9.0165 11,457 103.3K 11,665
14 Dec 20 Wright Richard M. Incentive Stock Option Common Stock Option exercise Dispose M No No 2.78 9,375 26.06K 20,625
14 Dec 20 Wright Richard M. Incentive Stock Option Common Stock Option exercise Dispose M No No 9.0165 11,457 103.3K 6,876
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No No 10.38 14,400 149.47K 14,400
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

CLDX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.9% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 127 90 +41.1%
Opened positions 53 36 +47.2%
Closed positions 16 18 -11.1%
Increased positions 32 25 +28.0%
Reduced positions 24 13 +84.6%
13F shares
 Current Prev Q Change
Total value 644.99M 470.29M +37.1%
Total shares 36.81M 31.71M +16.1%
Total puts 408.6K 205.2K +99.1%
Total calls 592.8K 454.3K +30.5%
Total put/call ratio 0.7 0.5 +52.6%
Largest owners
 Shares Value Change
RTW Investments 3.42M $59.97M +9.7%
Redmile 2.71M $47.51M +36.3%
Adage Capital Partners GP, L.L.C. 2.5M $43.8M +22.0%
Eventide Asset Managment 1.84M $32.19M +262.9%
STT State Street 1.81M $31.72M +7030.7%
Vanguard 1.77M $30.97M +2.6%
Acuta Capital Partners 1.63M $28.51M +5.3%
Citadel Advisors 1.4M $24.47M +5453.0%
Ikarian Capital 1.36M $23.92M -7.1%
Vivo Capital 1.29M $22.63M -25.0%
Largest transactions
 Shares Bought/sold Change
BVF 0 -3.07M EXIT
STT State Street 1.81M +1.78M +7030.7%
Citadel Advisors 1.4M +1.37M +5453.0%
Eventide Asset Managment 1.84M +1.33M +262.9%
POLR Polar Capital 0 -1.25M EXIT
Logos Global Management 0 -1.2M EXIT
Octagon Capital Advisors 1.04M +1.04M NEW
Marshall Wace North America 1.28M +1.03M +403.1%
Polar Capital 1M +1M NEW
Redmile 2.71M +722.42K +36.3%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Immunomedics • Astrazeneca • Roche • Nektar Therapeutics • Novartis • Stemline Therapeutics • Arrogene • Heat Biologics • Tesaro
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Academy, accuracy, Aid, al, allergic, allosteric, amplifying, Answer, Anthony, antihistamine, asymptomatic, Bartlett, breaking, bridging, Brownlie, carryback, Cavanaugh, Chair, Chancery, cholinergic, circulating, cold, ColdU, compelling, Complaint, Connemara, Conrad, contact, contending, context, count, Counterclaim, covenant, Crowley, cultural, cutoff, dealing, declaratory, dermatologic, DermNet, dermographism, description, Diane, downregulated, duly, EAACI, Elizabeth, enzyme, epinephrine, essence, Exhibit, featured, forward, Freddy, FricTest, Germany, Gilead, hallmark, hard, Harry, Hautarzt, hemoglobin, Herbert, herewith, HIV, immunosuppression, immunosuppressive, Importantly, Interferon, intervention, intravenously, isolated, itch, itching, Jimenez, Jr, Karen, Keith, led, Linkbase, Margo, Marino, Marucci, mirror, move, neuroinflammation, neutrophil, NIH, notification, omitted, onsite, ophthalmic, Org, overdosage, pancreatic, Penner, pharmacodynamic, PK, plasma, PN, President, profound, proper, properly, provocation, prurigo, pruritic, pts, reaction, repetition, resolved, respiratory, Richard, ROW, Rule, Sarah, SBIR, SCCHN, schema, SD, Senior, sensory, serum, shaking, Shareholder, shipment, shortly, situation, spontaneously, SRS, summer, Sunshine, sweating, synthesized, Taxonomy, temperature, TGFb, thereunto, TME, tryptase, undersigned, unjust, untreated, Verified, Vice, week, Weller, white, Wright, XBRL, Young
Removed: added, aimed, American, animal, appealed, ASCO, breast, carcinoma, CBR, CT, cytotoxic, death, developmental, diarrhea, DOR, enhance, ensuing, epitope, Erbitux, evolution, formation, Frontier, gastric, HPV, hyperproliferative, IAVI, inhibition, inInternal, kill, liver, lowered, mechanism, median, medimmune, melanoma, modulation, newly, objective, opposition, oral, ORR, OS, ourin, packaged, PFS, pharmacologic, poor, post, provisional, rash, registering, regulating, release, renal, resistance, reversal, Salk, Simon, slower, supplemental, thyroid, tiered, unclear
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
26 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
7 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18

Current reports

View all
8-K
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
29 Mar 21
8-K
Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel
4 Jan 21
8-K
Other Events
6 Nov 20
8-K
Celldex Provides Corporate Update and Reports Third Quarter 2020 Results
5 Nov 20
8-K
Other Events
18 Aug 20
8-K
Celldex Provides Corporate Update and Reports Second Quarter 2020 Results
6 Aug 20
8-K
Departure of Directors or Certain Officers
18 Jun 20
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
16 Jun 20
8-K
Other Events
15 Jun 20
8-K
Other Events
12 Jun 20

Registration and prospectus

View all
S-3ASR
Automatic shelf registration
6 Nov 20
S-8
Registration of securities for employees
26 Jun 20
424B5
Prospectus supplement for primary offering
16 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
12 Jun 20
S-3/A
Shelf registration (amended)
11 Jun 20
424B5
Prospectus supplement for primary offering
27 Mar 20
S-3
Shelf registration
6 Dec 19
S-8
Registration of securities for employees
21 Jun 19

Proxies

View all
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
7 May 19
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
18 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
PRE 14A
Preliminary proxy
16 Apr 17
DEF 14A
Definitive proxy
20 Apr 16
DEF 14A
Definitive proxy
22 Apr 15
DEF 14A
Definitive proxy
8 Apr 14

Other

View all
EFFECT
Notice of effectiveness
15 Jun 20
CORRESP
Correspondence with SEC
11 Jun 20
UPLOAD
Letter from SEC
11 Dec 19
CT ORDER
Confidential treatment order
19 Apr 18
EFFECT
Notice of effectiveness
12 Feb 17
EFFECT
Notice of effectiveness
12 Feb 17
CORRESP
Correspondence with SEC
8 Feb 17
CORRESP
Correspondence with SEC
8 Feb 17
UPLOAD
Letter from SEC
5 Feb 17
CORRESP
Correspondence with SEC
11 Jan 17

Ownership

View all
SC 13G
Celldex Therapeutics / Cowen Financial Products ownership change
25 Feb 21
SC 13G
Celldex Therapeutics / Redmile ownership change
16 Feb 21
SC 13G/A
Celldex Therapeutics / Ikarian Capital ownership change
12 Feb 21
SC 13G/A
Celldex Therapeutics / RTW INVESTMENTS ownership change
12 Feb 21
SC 13G/A
Celldex Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change
11 Feb 21
SC 13G/A
Celldex Therapeutics / ADAGE CAPITAL PARTNERS GP, L.L.C. ownership change
11 Feb 21
SC 13G/A
Celldex Therapeutics / RENAISSANCE TECHNOLOGIES ownership change
10 Feb 21
3
Celldex Therapeutics / Freddy A. Jimenez ownership change
4 Jan 21
4
Celldex Therapeutics / Richard M. Wright ownership change
16 Dec 20
SC 13G
Celldex Therapeutics / Logos Global Management ownership change
22 Oct 20

Patents

View all
APP
Utility
Methods of Treating Cancer with Dendritic Cell Mobilizing Agents
18 Mar 21
Methods of treating cancer comprising administering to patients a dendritic cell mobilizing agent (e.g., Flt3 ligand) in combination with radiation and/or immunoregulatory agents (e.g., checkpoint inhibitors), are disclosed.
GRANT
Utility
Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
9 Mar 21
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
GRANT
Utility
Nucleic acids encoding agonistic antibodies that bind CD40
14 Dec 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
APP
Utility
Anti-kit Antibodies and Uses Thereof
9 Dec 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
APP
Utility
Agonistic Antibodies That Bind Human CD40 and Uses Thereof
2 Dec 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.

Transcripts

View all
2020 Q2
Earnings call transcript
6 Aug 20
2019 Q2
Earnings call transcript
8 Aug 19
2018 Q4
Earnings call transcript
7 Mar 19
2018 Q2
Earnings call transcript
8 Aug 18
2017 Q3
Earnings call transcript
7 Mar 18

Reddit threads

Pro users get this 30m faster